Population pharmacokinetics of amphotericin B lipid complex in neonates. - Wikidata - awgldk - TriplyDB

Population pharmacokinetics of amphotericin B lipid complex in neonates.

Population pharmacokinetics of amphotericin B lipid complex in neonates.

http://www.wikidata.org/entity/Q34228332

about

Treatment and prophylaxis of invasive candidiasis Neonatal candidiasis: diagnosis, prevention, and treatment Advances in the treatment of invasive neonatal candidiasis Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications Pharmacokinetics of an elevated dosage of micafungin in premature neonates.Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology Population pharmacokinetics of micafungin in neonates and young infants Population pharmacokinetics of teicoplanin in children.Management of neonatal candidiasis. Neonatal Candidiasis Study Group Antifungal therapy and outcomes in infants with invasive Candida infections.Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing.Pharmacokinetics of antifungal agents in children.CNS pharmacokinetics of antifungal agents.Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.Clinical pharmacology of antifungal agents in pediatric patients.Amphotericin B use in children: conventional and lipid-based formulations.Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy.Invasive aspergillosis in children with acquired immunodeficiencies.The use of antifungal therapy in neonatal intensive care.Population pharmacokinetic analysis during the first 2 years of life: an overview.Old and new: appropriate dosing for neonatal antifungal drugs in the nursery.Considerations in the pharmacologic treatment and prevention of neonatal sepsis.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.Invasive candidiasis and candidaemia in neonates and children: update on current guidelines.Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014.Clinical pharmacology of antifungal agents to overcome drug resistance in pediatric patients.Pharmacokinetic considerations in treating invasive pediatric fungal infections.Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy.Differential transcriptional profiles induced by amphotericin B formulations on human monocytes during response to hyphae of Aspergillus fumigatus.Pediatric Invasive Candidiasis: Epidemiology and Diagnosis in Children.

P2860

Q27001567-2BFEDA5B-65FD-45E3-B88B-7DD9958C33E6 Q27008471-E7E64F4D-3ECD-4334-A0B1-5C5D66B336E9 Q27022585-B7E38D5C-314A-45C7-9EED-F5444064982B Q27025299-8697FD08-271F-4050-84D3-2FDC063EF06F Q30436332-DCD35080-0A59-4690-BF27-F8DF519B32D1 Q33827819-CE8EFBF5-E0EB-4CBF-8C00-AC33F8F8B526 Q33876608-0D047EB9-C726-4173-A271-1072B5441691 Q34596321-F68B6D9F-1F98-46D3-B8A4-CD14E81F9551 Q34680771-EC9FE44F-22C1-42FF-939A-1B1E54C419FD Q35897495-507EC30F-FF9C-4564-B51E-FC49B773ADBD Q36094957-6F1D11B7-72BC-41DA-BA8F-420B891A8E5A Q36163345-ED17726A-4B03-4BB9-8D6D-25082EE20197 Q36909333-E5865372-3DFA-4C9C-AFDA-0807021BA5EE Q36948094-A71414B5-294C-4C56-A9DA-8B29C220069B Q36968140-D883B590-823B-4474-8F3D-4C8E05F94BE2 Q37854727-F7123562-A5D4-4BCD-8677-B36A43D4D83E Q37889382-28A04686-2DE3-4DC2-B403-6EA45F57BD9E Q37954958-70A6EE45-ECE1-4726-B244-208CB7CF4AE3 Q37985070-B90895AF-FE85-444F-8125-B3E11A3FE605 Q38062388-5C18D03C-AD78-41F3-BC98-F411AFF81FAC Q38117791-280A3E12-B785-4253-807A-F57C0C12DA3D Q38161849-E1DD47B0-9F1F-45FE-8500-8D5755454B1C Q38193337-8E2F3B37-219F-47FF-8C9D-BD9F14DFA96C Q38215682-C0C7752C-F5E7-48AF-897E-85E384FBAE1D Q38263282-08094AA0-579A-4FAB-B079-93FE02B060DB Q38284461-3355EF1E-1976-4B9D-BC03-A196B3D0B429 Q38314467-947DD657-80FA-4746-B13C-0619845AAEA6 Q38816614-27372344-63C1-4F23-A584-43A711DA36E6 Q39471413-20B8302D-5586-4CFD-A814-41E2681AA74C Q39661366-EDB82E7C-44DD-49C7-A3B3-44B8AB0D187B Q49182676-CD475DB4-4D2A-4BB1-84BA-A96DE844C1AA

P2860

Population pharmacokinetics of amphotericin B lipid complex in neonates.

http://www.wikidata.org/entity/Q34228332

description

2005 nî lūn-bûn

@nan

2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Population pharmacokinetics of amphotericin B lipid complex in neonates.

@ast

Population pharmacokinetics of amphotericin B lipid complex in neonates.

@en

Population pharmacokinetics of amphotericin B lipid complex in neonates.

@nl

type

label

Population pharmacokinetics of amphotericin B lipid complex in neonates.

@ast

Population pharmacokinetics of amphotericin B lipid complex in neonates.

@en

Population pharmacokinetics of amphotericin B lipid complex in neonates.

@nl

prefLabel

Population pharmacokinetics of amphotericin B lipid complex in neonates.

@ast

Population pharmacokinetics of amphotericin B lipid complex in neonates.

@en

Population pharmacokinetics of amphotericin B lipid complex in neonates.

@nl

P1433

Q34228332-FEAF2F5A-4A43-4A2E-907E-84340E780F0D

P1476

Q34228332-AACD101C-6E9B-4A30-B0BF-4EC76D406B42

P2093

Q34228332-3EB6A897-8AF6-40BE-960F-699724837D92

Q34228332-6A63D06D-E895-4705-B52F-0257D3D594BE

Q34228332-9CB65773-4EA8-4938-80F4-809C5A11001B

Q34228332-BA74EF51-C832-485E-B71B-72AEC4DAE0B4

Q34228332-E8B8B93D-AEB6-4F76-A852-B3E74ACC0439

Q34228332-F5F0D683-B7E3-46A8-AD96-8FC2290BE3B9

P2860

Q34228332-07652212-022B-4072-8BB7-F2720FD9EF1B

Q34228332-0B81F95B-E7B3-4F08-B4A3-840478067589

Q34228332-19FCBAE4-3180-4C23-B507-E2B4204D183A

Q34228332-2273B95A-42BA-4DFA-9337-588E5DB090B6

Q34228332-2CBDB0FE-6821-421C-B101-6F28266D70D4

Q34228332-2D6F95FA-9AE2-4E9E-A302-5815DC031DDD

Q34228332-2DB6944B-E79D-444A-8B02-2CC63450023C

Q34228332-2F0CBA2D-959E-41CC-A76E-EBC2BD5997A4

Q34228332-3074F9C1-FE95-4CD4-A79A-CF474A5CF0D0

Q34228332-31649381-C086-4E6C-8360-0EDCE81160D1

P304

Q34228332-65906FC5-B8CD-4C8D-8385-74A6C5E596EB

P31

Q34228332-CC4E7A96-8F45-4FA9-9BFD-6B2FE935ACE3

P356

Q34228332-ED3A43A0-385F-4E09-AFAC-C7B4E652AF41

P407

Q34228332-9749C3F2-A108-4608-B379-0118FA6962F4

P433

Q34228332-283DBE46-E5FA-40EA-BC51-F3C83BA636DD

P478

Q34228332-FB1DE2AF-B245-4579-BFFA-2619C3BAF794

P577

Q34228332-C5B28779-00F7-4699-95D3-827CC54F6AA6

P698

Q34228332-896E1141-77C7-40FF-B858-07FE755A5773

P932

Q34228332-29640998-BCFA-4C37-9B22-64AA226AF72D

P356

AAC.49.12.5092-5098.2005

P1433

Antimicrobial Agents and Chemotherapy

P1476

Population pharmacokinetics of amphotericin B lipid complex in neonates.

@en

P2093

Andreas H Groll

http://www.w3.org/2001/XMLSchema#string

Felice C Adler-Shohet

http://www.w3.org/2001/XMLSchema#string

Georg Hempel

http://www.w3.org/2001/XMLSchema#string

Gudrun Würthwein

http://www.w3.org/2001/XMLSchema#string

Jay M Lieberman

http://www.w3.org/2001/XMLSchema#string

Thomas J Walsh

http://www.w3.org/2001/XMLSchema#string

P2860

A general model for the origin of allometric scaling laws in biology

Fluconazole prophylaxis against fungal colonization and infection in preterm infants.

Fungal infection in the very low birthweight infant.

Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.

Candida isolates from neonates: frequency of misidentification and reduced fluconazole susceptibility.

Population pharmacokinetics of panipenem in neonates and retrospective evaluation of dosage.

Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.

Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.

Dose-dependent pharmacokinetics of amphotericin B lipid complex in rabbits.

A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections.

P304

5092-5098

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.49.12.5092-5098.2005

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16304177

http://www.w3.org/2001/XMLSchema#string

P932

1315949

http://www.w3.org/2001/XMLSchema#string